Drugs / TAK-202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02723006 | Jun 2016 → May 2018 | melanoma | Millennium Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02723006 ↗ |
| Route | Intravenous | “TAK-202 (plozalizumab) 2 milligram (mg), intravenous” NCT02723006 ↗ |